NCT07023614View on ClinicalTrials.gov

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
DRUG

Ninerafaxstat 200mg MR

Ninerafaxstat 200mg Modified Release tablet administered BID

DRUG

Placebo

Matching placebo tablet administered BID

Trial Locations (2)

63110

RECRUITING

Imbria Investigational Site, St Louis

01805

RECRUITING

Imbria Investigational Site, Burlington

Sponsors
All Listed Sponsors
lead

Imbria Pharmaceuticals, Inc.

INDUSTRY